** Drugmaker BioCryst Pharmaceuticals' BCRX.O shares fall 11% to $8.20
** Co posts Q4 net loss of 13 cents per share, compared with analysts' estimates of a loss of 6 cents per share, according to data compiled by LSEG
** Separately in a filing, co discloses it received a notice from India's Annora Pharma in January regarding Annora's submission of an application to the FDA seeking approval to manufacture, use or sell a generic version of BCRX's Orladeyo before the expiration of patents
** The letter alleges that the patents, which expire in 2039, are invalid
** Orladeyo is used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes severe swelling in the body
** BCRX intends to vigorously defend its intellectual property rights protecting Orladeyo, it said
** Co posts Q4 revenue of $131.5 million on strong sales for Orladeyo, compared with analysts' estimates of $130.2 million
** Expects 2025 total revenue between $560 million and $575 million vs analysts' estimates $545 million
** BCRX rose 63% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.